Overview

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular

Status:
Completed

Trial end date:
2019-07-22

Target enrollment:

Participant gender:

Summary

Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO grade 3) as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify predictive molecular subtypes

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Collaborator:

Merck KGaA, Darmstadt, Germany

Treatments:

Avelumab